In the past week, ORIC stock has gone down by -7.96%, with a monthly gain of 30.15% and a quarterly surge of 14.61%. The volatility ratio for the week is 9.11%, and the volatility levels for the last 30 days are 9.41% for ORIC Pharmaceuticals Inc The simple moving average for the last 20 days is 7.88% for ORIC stock, with a simple moving average of 15.50% for the last 200 days.
Is It Worth Investing in ORIC Pharmaceuticals Inc (NASDAQ: ORIC) Right Now?
Company’s 36-month beta value is 1.20.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ORIC is 45.95M, and currently, short sellers hold a 22.89% ratio of that floaft. The average trading volume of ORIC on February 05, 2025 was 518.99K shares.
ORIC) stock’s latest price update
ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has seen a rise in its stock price by 5.91 in relation to its previous close of 10.15. However, the company has experienced a -7.96% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-27 that SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:
Analysts’ Opinion of ORIC
Many brokerage firms have already submitted their reports for ORIC stocks, with Wells Fargo repeating the rating for ORIC by listing it as a “Overweight.” The predicted price for ORIC in the upcoming period, according to Wells Fargo is $20 based on the research report published on October 31, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see ORIC reach a price target of $20. The rating they have provided for ORIC stocks is “Buy” according to the report published on September 06th, 2024.
ORIC Trading at 15.35% from the 50-Day Moving Average
After a stumble in the market that brought ORIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.44% of loss for the given period.
Volatility was left at 9.41%, however, over the last 30 days, the volatility rate increased by 9.11%, as shares surge +25.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.92% upper at present.
During the last 5 trading sessions, ORIC fell by -7.96%, which changed the moving average for the period of 200-days by +10.14% in comparison to the 20-day moving average, which settled at $9.96. In addition, ORIC Pharmaceuticals Inc saw 33.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ORIC starting from Piscitelli Dominic, who sale 8,851 shares at the price of $8.28 back on Dec 16 ’24. After this action, Piscitelli Dominic now owns 106,764 shares of ORIC Pharmaceuticals Inc, valued at $73,298 using the latest closing price.
Multani Pratik S, the Chief Medical Officer of ORIC Pharmaceuticals Inc, sale 8,850 shares at $8.28 during a trade that took place back on Dec 16 ’24, which means that Multani Pratik S is holding 46,765 shares at $73,293 based on the most recent closing price.
Stock Fundamentals for ORIC
Current profitability levels for the company are sitting at:
- -87.62 for the present operating margin
- 0.48 for the gross margin
The net margin for ORIC Pharmaceuticals Inc stands at -77.94. The total capital return value is set at -0.48. Equity return is now at value -45.98, with -41.59 for asset returns.
Based on ORIC Pharmaceuticals Inc (ORIC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -35.01. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -67.85.
Currently, EBITDA for the company is -109.75 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 466.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.15.
Conclusion
In a nutshell, ORIC Pharmaceuticals Inc (ORIC) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
